James M McKiernan MD

Urology•New York, NY

Surgical Oncology

John K. Lattimer Professor and Chair Department of Urology Columbia University College of P&S Urologist-In-Chief NYPH

Request appointment

161 Fort Washington AvenueNew York, NY 10032
Book by Phone+1(570) 776-0805

Overview of Dr. McKiernan

Dr. James McKiernan is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian Hudson Valley Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Allen Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 33 years. He is one of 208 doctors at New York-Presbyterian Hospital and one of 8 doctors at NewYork-Presbyterian/Allen Hospital who specialize in Urology. He has more than 100 publications and over 500 citings.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1995 - 1999
New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1993 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993
Johns Hopkins UniversityB.A., Biology, 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2021 - 2027
NY State Medical License 1996 - 2027
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2014, 2016-2017

Clinical Trials

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
COMPLETED
PHASE1, PHASE2
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
TERMINATED
PHASE2, PHASE3
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Start of enrollment: 2014 Apr 09
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Nonmuscle-Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant ...
Benjamin I Joffe, Srinath-Reddi Pingle, Caroline Laplaca, John R Christin, Clémentine Le Coz
The Journal of Urology. 2026-08-26
Reply by Authors.
G Joel DeCastro, James M McKiernan
The Journal of Urology. 2026-08-10
5 citations
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang
Cell Reports. Medicine. 2026-03-17

Journal Articles

Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy
Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner..., Urol, 7/22/2014
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer
Stevenson SM, Danzig MR, Ghandour RA, Deibert CM, Joel Decastro G, Benson MC, McKiernan JM, Urol Oncol, 7/3/2014
Phase II Trial of Intravesical Nanoparticle Albumin-Bound (nab-) Paclitaxel for the Treatment of Non-Muscle Invasive Urothelial Carcinoma of the Bladder after BCG Trea...
McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, Badalato GM, Roychoudhury A, Decastro GJ, Benson MC, J Urol, 7/1/2014

Books/Book Chapters

Staging Manual, Genitourinary System
Chapter: American Joint Committee on Cancer TNM
McKiernan JMEdition 7th,2009
Campbell's Urology
Chapter: Continent Cutaneous Urinary Diversion
Benson MC, McKiernan JM, Olsson CAEdition 9th,2006
Campbell's Urology
Chapter: Surgery of Testicular Neoplasms
Sheinfeld J, McKiernan JM, Bosl GJEdition 8th,2002

Authored Content

Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018

Press Mentions

Columbia Medical School Freezes Hiring and Other Spending Amid Threat of Federal CutsFebruary 13th, 2025
$New Treatment Options Emerging for Patients with Refractory NMIBC$
New Treatment Options Emerging for Patients with Refractory NMIBCMay 13th, 2022
Bio-Techne Announces Publication of ExoDx Prostate Test Study in Patients with Prior Negative Prostate BiopsySeptember 23rd, 2020